Innovative Medicines Canada files against federal plans
The lobbying group Innovative Medicines Canada has announced its lawsuit against plans to lower drug prices in the country.
List view / Grid view
The lobbying group Innovative Medicines Canada has announced its lawsuit against plans to lower drug prices in the country.
Bacteriostatic Water is being recalled because of a lack of sterilisation confirmation for some vials.
Research has found that the worldwide LC-MS market will be worth $2750 million by the end of the forecast period in 2024.
The Kymriah (tisagenlecleucel) treatment has received a positive appraisal from the Scottish Medicines Consortium, after EMA approval last year.
Novartis reportedly knew of discrepancies in the Zolgensma data it had submitted to the FDA but delayed informing regulators so has announced alterations to its processes.
Both the intravenous and oral formulations of the antifungal candidate, fosmanogepix, have been granted Fast Track designation by the FDA.
A team has developed a microrobot that is effective at targeting specific areas, so could be used in hyperthermia therapies when treating cancers.
New nanocapsules are a promising platform for many types of gene therapies due to their small size and superior stability.
Two Tennessee companies have been prevented from distributing drugs after a complaint they were supplying unapproved medications.
The FDA has approved the first treatment for interstitial lung disease associated with systemic sclerosis or scleroderma.
Generic treatments for blood/bone marrow disorders and acute nausea and vomiting associated with chemotherapy have gained FDA approval.
The EMA will assess the marketing authorisation for the medication to see whether it is a cause of skin cancer in patients.
The biologic treatment ustekinumab has been granted an expanded use for ulcerative colitis within the EU.
Ahngook Pharmaceuticals reportedly held clinical trials on its employees without their consent, leading to the arrest of the company president.
The FDA has awarded a breakthrough therapy designation to an investigational prophylactic vaccine to treat respiratory syncytial virus in seniors.